CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 75 enrolled
Drug / intervention
RSV A Memphis 37 +2 morebiological
Likely dose
RSV A Memphis 37 1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02755948
NCT02755948N/ACompleted

Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge

Imperial College London·interventional·Posted Apr 29, 2016·Updated Dec 6, 2024

In Brief

A clinical study evaluating RSV A Memphis 37, Influenza A/California/04/2009-likw (H1N1), and 1 other intervention for Respiratory Syncytial Virus Infections and Influenza, Human. Completed, enrolled 75 participants across 1 site.

Detailed Summary

Respiratory viruses including influenza and respiratory syncytial virus (RSV) are among the most important causes of severe disease globally, infecting everyone repeatedly throughout life. Understanding of how to prevent infection is incomplete but boosting immunity with vaccines remains the best strategy. T cells have been shown in animals to be essential for clearing respiratory viral infection and are likely to be helpful if stimulated by vaccines. However, where these cells originate from and how they develop in the human lung are still unclear. The investigators will inoculate volunteers with influenza or RSV to examine the relationship between T cells in their blood and lungs and the outcome of infection. By tracking these specialised cells, the investigators aim to develop a better understanding of how they are generated in order to harness them with future vaccines.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2016
Enrollment StartApr 1, 2012
Primary CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 10.2 years ago

Interventions

RSV A Memphis 37biological

Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops

Influenza A/California/04/2009-likw (H1N1)biological

Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops

Influenza A/Belgium/4217/2015 (H3N2)biological

Good Manufacturing Practices-certified Influenza A/Belgium/4217/2015 (H3N2) 3.5x10\^6 TCID50 in 1 mL in DPBS delivered by intranasal drops